Analyst Price Target is $50.00
▼ -3.27% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Vericel in the last 3 months. The average price target is $50.00, with a high forecast of $65.00 and a low forecast of $31.00. The average price target represents a -3.27% upside from the last price of $51.69.
Current Consensus is
The current consensus among 6 contributing investment analysts is to buy stock in Vericel. This rating has held steady since September 2019, when it changed from a Hold consensus rating.
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.